|
个人信息Personal Information
教授 博士生导师 硕士生导师
性别：男
毕业院校：山东大学
学历：研究生(博士)毕业
学位：医学博士学位
在职信息：在职
所在单位：药学院
入职时间：2013-02-28
联系方式：zhangyingjie@sdu.edu.cn
扫描关注
-
1. 药物化学
2. 化学生物学
- . Discovery of epigenetic modulators targeting HDACs and EZH2 simultaneously for the treatment of hematological malignancies. Bioorganic Chemistry, 153, 2025.
- . Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer. Journal of Medicianal Chemistry, 66, 2024.
- . Discovery of the First Irreversible HDAC6 Isoform Selective Inhibitor with Potent Anti-Multiple Myeloma Activity. J. Med. Chem. , 66, 10080, 2023.
- Anil Kumar Marapaka. Development of peptidomimetic hydroxamates as PfA-M1 and PfA-M17 dual inhibitors: Biological evaluation and structural characterization by cocrystallization. CHINESE CHEMICAL LETTERS, 2550, 2022.
- 薛霞. Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents. Investigational New Drugs , 40, 10-20, 2022.
- 许启富. Inhibitors of the GTPase KRAS(G12C) in cancer: a patent review (2019-2021). Expert Opinion on Therapeutic Patents, 32, 475, 2022.
- 通过抑制自噬克服胰腺导管腺癌适应性耐药的组蛋白去乙酰化酶10亚型选择性抑制剂的发现和研究, 2024/08/23-2028/12/31
- 具有抗肝细胞癌耐药、复发和转移优势的组蛋白去乙酰化酶11亚型选择性抑制剂的发现和研究, 2022/09/07-2026/12/31
- HDAC11亚型选择性抑制剂的研发, 2024/09/13-2028/09/30
- EZH2抑制剂Tazemetostat的合成工艺研究, 2022/03/21-2025/12/31
- 基于组蛋白去乙酰化酶HDACs为靶标的抗癌药物研究, 2014/01/01-2016/12/31
- 以HDACs为靶标的抗肿瘤先导化合物ZYJ-34c的成药性研究, 2013/08/15-2016/12/31